VA, Prostate Cancer Foundation Partner to Expand Clinical Research
News Nov 30, 2016
The Department of Veterans Affairs (VA) announced an important and substantial partnership with the Prostate Cancer Foundation (PCF) to prevent, screen and promote research to speed the development of treatments and cures for prostate cancer among Veterans. Announcement of the partnership was made during Launch Pad: Pathways to Cancer InnoVAtion, a joint VA/PCF summit held today that brings together world-class oncology experts, corporate and non-profit partners to discuss research, big data, technology and clinical solutions to advance screening, diagnostics and care coordination for cancer and to promote the implementation of best practices across the VA healthcare system.
As part of the summit, PCF announced a $50-million precision oncology initiative to expand prostate cancer clinical research among Veterans to speed the development of new treatment options and cures for prostate cancer patients. The agreement signed today is the first partnership between PCF and VA, and it comes at a time when an estimated 12,000 Veterans each year are diagnosed with prostate cancer, making it the most frequently diagnosed cancer among Veterans. In particular, African-Americans are 64 percent more likely to develop prostate cancer compared to any other race or ethnicity and 2.4 times more likely to die from the disease.
“Fighting and treating cancer among our Veterans is a team effort, which is why this Launch Pad event and this partnership are so important,” said VA Secretary Robert A. McDonald. To effectively serve our Veterans and to keep VA on the cutting edge of medical research, we need government, corporate, and non-profit organizations working together. We are truly grateful to the Prostate Cancer Foundation for this important show of support. Our work together will save Veterans’ lives.”
The goals of the PCF partnership are to increase the number of Veterans Health Administration (VHA) investigators applying to PCF for funding; increase the number of VHA facilities involved in precision medicine/prostate cancer clinical trials; increase the number of Veterans enrolled in studies, providing veteran specimens or data used in studies as well as increase the number of minorities enrolled in PCF studies; and increase the number of early career scientists working on prostate cancer research.
“Our goal is to increase our scientific understanding of prostate cancer among Veterans and to kick-start the development of precision medicine treatments for them, as well as the general population,” said Jonathan W. Simons, MD, President and Chief Executive Officer, PCF. “This agreement will open new doors for the research community to work with Veterans facing a life-threatening disease and ultimately reduce the disease burden on America’s Veterans.”
Story from the U.S. Department of Veterans Affairs. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE